Cargando…

The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis

The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Mona P., Abi Khalil, Charbel, Refaat, Marwan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/
https://www.ncbi.nlm.nih.gov/pubmed/29270438
http://dx.doi.org/10.1155/2017/9257930
_version_ 1783282118690865152
author Nasrallah, Mona P.
Abi Khalil, Charbel
Refaat, Marwan M.
author_facet Nasrallah, Mona P.
Abi Khalil, Charbel
Refaat, Marwan M.
author_sort Nasrallah, Mona P.
collection PubMed
description The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner.
format Online
Article
Text
id pubmed-5705897
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57058972017-12-21 The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis Nasrallah, Mona P. Abi Khalil, Charbel Refaat, Marwan M. Biomed Res Int Review Article The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner. Hindawi 2017 2017-11-14 /pmc/articles/PMC5705897/ /pubmed/29270438 http://dx.doi.org/10.1155/2017/9257930 Text en Copyright © 2017 Mona P. Nasrallah et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nasrallah, Mona P.
Abi Khalil, Charbel
Refaat, Marwan M.
The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title_full The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title_fullStr The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title_full_unstemmed The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title_short The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
title_sort landscape of glucose-lowering therapy and cardiovascular outcomes: from barren land to metropolis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/
https://www.ncbi.nlm.nih.gov/pubmed/29270438
http://dx.doi.org/10.1155/2017/9257930
work_keys_str_mv AT nasrallahmonap thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis
AT abikhalilcharbel thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis
AT refaatmarwanm thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis
AT nasrallahmonap landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis
AT abikhalilcharbel landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis
AT refaatmarwanm landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis